{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T17:43:33Z","timestamp":1776620613890,"version":"3.51.2"},"reference-count":25,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"DOI":"10.1182\/blood.2019002799","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T15:01:53Z","timestamp":1579878113000},"page":"769-773","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-3932","authenticated-orcid":false,"given":"Rutger C.","family":"Melchers","sequence":"first","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rein","family":"Willemze","sequence":"first","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost S. P.","family":"Vermaat","sequence":"first","affiliation":[{"name":"Department of Haematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patty M.","family":"Jansen","sequence":"first","affiliation":[{"name":"Department of Pathology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurien A.","family":"Dani\u00ebls","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hein","family":"Putter","sequence":"first","affiliation":[{"name":"Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel W.","family":"Bekkenk","sequence":"first","affiliation":[{"name":"Department of Dermatology, Academic Medical Centre and Vrije University Medical Centre, Amsterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen R. M.","family":"de Haas","sequence":"first","affiliation":[{"name":"Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Horvath","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Medical Centre Groningen, Groningen, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"van Rossum","sequence":"first","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelus J. G.","family":"Sanders","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep C. J. M.","family":"Veraart","sequence":"first","affiliation":[{"name":"Department of Dermatology, Maastricht University Medical Centre, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4613","authenticated-orcid":false,"given":"Maarten H.","family":"Vermeer","sequence":"first","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen D.","family":"Quint","sequence":"first","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2020030512010361200_B1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"16","key":"2020030512010361200_B2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2020030512010361200_B3","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2020030512010361200_B4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaad.2015.09.013","article-title":"Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients","volume":"74","author":"Wieser","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2020030512010361200_B5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1634\/theoncologist.2015-0242","article-title":"Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis","volume":"21","author":"Cordel","year":"2016","journal-title":"Oncologist"},{"issue":"5","key":"2020030512010361200_B6","first-page":"331","article-title":"Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry","volume":"10","author":"Booken","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"2020030512010361200_B7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","article-title":"CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma","volume":"49","author":"Liu","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2020030512010361200_B8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bjh.14404","article-title":"Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience","volume":"176","author":"Hapgood","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2020030512010361200_B9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood.2019000785","article-title":"How I treat primary cutaneous CD30+ lymphoproliferative disorders","volume":"134","author":"Shinohara","year":"2019","journal-title":"Blood"},{"issue":"suppl 4","key":"2020030512010361200_B10","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"issue":"15","key":"2020030512010361200_B11","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2020030512010361200_B12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2020030512010361200_B13","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2020030512010361200_B14","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1080\/10428194.2017.1393671","article-title":"Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital","volume":"59","author":"Gleeson","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020030512010361200_B15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/16078454.2019.1613290","article-title":"Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma","volume":"24","author":"Wang","year":"2019","journal-title":"Hematology"},{"key":"2020030512010361200_B16","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.2147\/OTT.S141053","article-title":"Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review","volume":"11","author":"Donato","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"10168","key":"2020030512010361200_B17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"2020030512010361200_B18","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"2020030512010361200_B19","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1080\/10428194.2019.1599112","article-title":"Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC","volume":"60","author":"Garciaz","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2020030512010361200_B20","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2020030512010361200_B21","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"key":"2020030512010361200_B22","article-title":"NCCN Guidelines: T-cell lymphomas, version 2.2019","author":"Horwitz","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"32","key":"2020030512010361200_B23","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020030512010361200_B24","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jamadermatol.2017.3593","article-title":"Brentuximab vedotin for patients with refractory lymphomatoid papulosis: an analysis of Phase 2 results","volume":"153","author":"Lewis","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"10094","key":"2020030512010361200_B25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/10\/769\/1717851\/bloodbld2019002799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/10\/769\/1717851\/bloodbld2019002799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T17:01:16Z","timestamp":1583427676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/10\/769\/440468\/Outcomes-of-rare-patients-with-a-primary-cutaneous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,3,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019002799","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}